Travere Therapeutics, Inc. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -9.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.37 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $-0.30 | $-0.39 | -30.0% | Miss | Q1 FY26 call |
| Q3 FY25 | not reported | $0.28 | not reported | not reported | |
| Q2 FY25 | $-0.28 | $-0.14 | +50.0% | Beat | |
| Q1 FY25 | $-0.55 | $-0.47 | +14.6% | Beat | |
| Q4 FY24 | $-0.58 | $-0.73 | -25.9% | Miss | |
| Q3 FY24 | $-0.70 | $-0.70 | +0.0% | Beat | |
| Q2 FY24 | $-0.87 | $-0.90 | -3.5% | Miss | |
| Q1 FY24 | $-0.98 | $-1.76 | -79.6% | Miss | |
| Q4 FY23 | $-1.27 | $-1.16 | +8.7% | Beat | |
| Q3 FY23 | $-1.09 | $-1.17 | -7.3% | Miss | |
| Q2 FY23 | $-1.16 | $-1.13 | +2.6% | Beat |
Back to TVTX overview · TVTX holders · TVTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.